Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency-Reference-Cited by-同舟云学术

Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency

Published:2024-02-20 Issue:8 Volume:134 Page:
ISSN:1558-8238
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Aminov Sarah,Giricz Orsi^ORCID,Melnekoff David T.,Sica R. Alejandro,Polishchuk Veronika,Papazoglu Cristian,Yates Bonnie,Wang Hao-Wei,Sahu Srabani,Wang Yanhua,Gordon-Mitchell Shanisha,Leshchenko Violetta V.,Schinke Carolina^ORCID,Pradhan Kith,Aluri Srinivas^ORCID,Sohn Moah,Barta Stefan K.^ORCID,Agarwal Beamon,Goldfinger Mendel,Mantzaris Ioannis,Shastri Aditi,Matsui William,Steidl Ulrich,Brody Joshua D.,Shah Nirali N.^ORCID,Parekh Samir,Verma Amit

Publisher

American Society for Clinical Investigation

Link

https://www.jci.org/articles/view/175199/files/pdf

Reference24 articles.

1. Acute lymphoblastic leukemia: a comprehensive review and 2017 update

2. Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19

3. Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies

4. Anti-CD19 resistance can “stem” from progenitors

5. A stem cell epigenome is associated with primary nonresponse to CD19 CAR T cells in pediatric acute lymphoblastic leukemia

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting;Molecular Therapy;2024-09

2. Oncotherapy resistance explained by Darwinian and Lamarckian models;Journal of Clinical Investigation;2024-04-15